<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the care of long-term testicular cancer survivors</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the care of long-term testicular cancer survivors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the care of long-term testicular cancer survivors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David J Vaughn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Linda A Jacobs, PhD, CRNP, FAAN</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larissa Nekhlyudov, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Ganz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H7365582"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Testicular cancer is the most curable solid tumor and the most common malignancy in males between the ages of 18 and 35. Testicular cancer is highly curable with a relative overall survival rate exceeding 96 percent at 10 years. This improvement in survival is attributable to treatment advances such as cisplatin-based chemotherapy. Following treatment for testicular cancer, oncologic follow-up is guided in part by the probability of relapse over time. Although most relapses occur within the first five years, late recurrences can occur.</p><p>Cancer survivorship issues evolve over time after completing therapy. During the period of oncologic follow-up, after active therapy or any time thereafter, patients with a history of testicular cancer may develop symptoms that affect quality of life or have abnormal findings on clinical examination [<a href="#rid1">1</a>]. The patient's clinicians and oncologists may be challenged with questions related to whether or not these symptoms or findings are due to prior treatment.</p><p>Late treatment-related complications in testicular cancer survivors are presented here. The discussion is intended for the management of patients who have completed the active phase of cancer therapy and have transitioned to receiving almost all of their care from their other clinicians. Acute treatment-related toxicity and posttreatment follow-up of males treated for testicular cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors"</a> and  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors"</a>.)</p><p>A general overview of cancer survivorship is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers"</a>.)</p><p class="headingAnchor" id="H773414376"><span class="h1">OVERVIEW OF TREATMENT</span><span class="headingEndMark"> — </span>The diagnosis of a testicular cancer is generally established with an inguinal orchiectomy, which also serves as the initial treatment for the primary tumor. The information obtained from surgical pathology is used to determine pathologic tumor stage  (<a class="graphic graphic_table graphicRef110731" href="/z/d/graphic/110731.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef110732" href="/z/d/graphic/110732.html" rel="external">table 2</a>). Following diagnosis, treatment is tailored based on the likelihood of recurrence and to minimize the long-term side effects. Key elements used to determine the treatment plan include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Histology (ie, seminoma versus nonseminomatous germ cell tumors [NSGCT]) (see  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Presence or absence of metastases</p><p class="bulletIndent1"><span class="glyph">●</span>Degree of elevation in serum tumor markers</p><p></p><p>Available treatment options for testicular cancer may include further surgical management such as retroperitoneal lymph node dissection (RPLND), radiation therapy (RT), and platinum-based chemotherapy. An overview of the treatment of testicular cancer is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>.)</p><p>Active surveillance following orchiectomy is an option specifically for males with stage I seminoma or NSGCT. (See  <a class="medical medical_review" href="/z/d/html/2950.html" rel="external">"Surveillance for stage I testicular germ cell tumors following orchiectomy"</a>.)</p><p class="headingAnchor" id="H536925901"><span class="h1">FERTILITY PRESERVATION</span><span class="headingEndMark"> — </span>Counseling regarding sperm banking as a means of fertility preservation is routinely done prior to initiation of any form of treatment in males of reproductive age. However, less than 30 percent of males actually choose to bank sperm and an even smaller proportion (10 percent) actually use banked sperm to father a child [<a href="#rid2">2,3</a>]. Despite this, many patients treated for testicular cancer go on to become fathers naturally with recovery of spermatogenesis achieved in 80 percent five years after diagnosis [<a href="#rid4">4,5</a>]. (See <a class="local">'Hypogonadism'</a> below.)</p><p class="headingAnchor" id="H536926018"><span class="h1">FOLLOW-UP POSTTREATMENT</span><span class="headingEndMark"> — </span>Follow-up care for males who have successfully completed therapy for testicular cancer consists of a surveillance schedule that includes history and physical examinations (including testicular examination), assessment of serum tumor markers including beta-human chorionic gonadotropin (hCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) if indicated, and radiographic studies. (See  <a class="medical medical_review" href="/z/d/html/2950.html" rel="external">"Surveillance for stage I testicular germ cell tumors following orchiectomy", section on 'Surveillance protocols'</a> and  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors", section on 'Guidelines for follow-up'</a>.)</p><p>Factors that influence the nature and intensity of follow-up after completion of initial definitive therapy include the histology (seminoma versus nonseminomatous germ cell tumor [NSGCT]), original risk stratification group (for males presenting with advanced disease  (<a class="graphic graphic_table graphicRef110732" href="/z/d/graphic/110732.html" rel="external">table 2</a>)), and treatment (particularly the use of surgery or radiation therapy to treat the retroperitoneal lymph nodes).</p><p>The intensity of follow-up is guided in part by the probability of relapse over time. For males with seminoma, the median time to relapse is 13 to 16 months. However, there is a wide range of relapse (between 2 and 108 months), with up to one-third of relapses occurring more than three years after completion of treatment [<a href="#rid6">6,7</a>]. By contrast, over 95 percent of relapses of NSGCTs occur within the first two years following orchiectomy [<a href="#rid8">8</a>].</p><p>Although most relapses occur within the first five years for both seminoma and NSGCT, late recurrences can occur [<a href="#rid9">9-11</a>]. Based on this type of observation, follow-up is most intensive during the first two years after treatment and then gradually decreases. Guidelines vary regarding the frequency of routine imaging or blood work for the long-term survivor of testicular cancer, particularly after the first five years have passed. However, most groups now recommend lifelong follow-up after completion of successful therapy because of the risk of late relapse. Therefore, cancer surveillance should be coordinated between the primary care clinician and the oncology team. (See  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors"</a>.)</p><p class="headingAnchor" id="H2639185"><span class="h1">SIDE EFFECTS OF TREATMENT</span></p><p class="headingAnchor" id="H1310897888"><span class="h2">Cumulative burden of morbidity</span><span class="headingEndMark"> — </span>Cisplatin-based chemotherapy is essential for cure for patients with metastatic testicular germ cell tumors. Since the 1970s, a large number of testicular cancer survivors have been exposed to cisplatin-based chemotherapy as part of their initial treatment. This exposure to <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> results in a range of toxicities [<a href="#rid12">12</a>]. In addition, circulating serum platinum remains at detectable levels for at least 20 years after treatment and may continue to contribute to additional toxicity for prolonged periods [<a href="#rid13">13</a>]. The use of cisplatin chemotherapy contributes to a cumulative burden of mortality in the testicular cancer survivors as well as to various organ-specific toxicities [<a href="#rid14">14</a>]. </p><p>In a multi-institution cohort of 1214 testicular cancer survivors, the frequency and severity of specific adverse events was analyzed, and this information was combined into a cumulative burden of morbidity score [<a href="#rid15">15</a>]. All of the males in this cohort had received cisplatin-based chemotherapy as a component of their initial treatment and were undergoing routine follow-up at the time of study inclusion. The most frequently identified adverse health outcomes included obesity, sensory neuropathy, tinnitus, hearing damage, Raynaud phenomenon, and pain. At a median follow-up of 4.2 years after completion of chemotherapy, approximately 20 percent of males had a high, very high, or severe cumulative burden of morbidity score, and only 5 percent had no adverse health outcomes. A high cumulative burden of morbidity score was strongly associated with worse self-reported health.</p><p class="headingAnchor" id="H773414440"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>Treatment with a platinum-based therapy regimen is associated with increased risk of hypertension and hypercholesterolemia [<a href="#rid16">16</a>]. Close cardiovascular follow-up in the first year following platinum-based chemotherapy is important to address modifiable cardiovascular risk factors in the long term [<a href="#rid17">17,18</a>]. (See  <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Cardiovascular'</a> and  <a class="medical medical_review" href="/z/d/html/17017.html" rel="external">"Cancer survivorship: Cardiovascular and respiratory issues"</a>.)</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Contrary to prior studies that demonstrated a higher risk of long-term cardiovascular effects among testicular cancer survivors, treatment with platinum based chemotherapy has been associated with increased cardiovascular mortality (due to both heart disease and cerebrovascular disease) following treatment [<a href="#rid16">16,19,20</a>]. As an example, one study of 15,006 patients identified using the Surveillance, Epidemiology, and End Results (SEER) program found that excess cardiovascular mortality was restricted to those treated with chemotherapy versus those treated with surgery. Similar cardiovascular risks were seen among those with more extensive disease and men who were older than 35 years at diagnosis (particularly those older than 50 years) [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another observational study of 5185 patients with germ cell cancer, treatment with <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (BEP) was associated with 44 percent increased risk of death from cardiovascular disease. In addition, the 20-year cumulative incidence of coronary heart disease or cerebrovascular accident after orchiectomy in patients undergoing surveillance, radiation therapy (RT), and BEP was 6.6, 9, and 7.9 percent, respectively [<a href="#rid16">16</a>]. </p><p></p><p class="headingAnchor" id="H1247931"><span class="h3">Metabolic syndrome</span><span class="headingEndMark"> — </span>The metabolic syndrome (insulin resistance syndrome or syndrome X) represents a cluster of risk factors that result in an increased incidence of, and mortality from, cardiovascular disease.</p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of the metabolic syndrome in long-term testicular cancer survivors was evaluated in a study that included 251 testicular cancer survivors (cases) and 360 healthy subjects (controls) [<a href="#rid21">21</a>]. Among cases, 174, 57, and 20 males were previously treated with combination chemotherapy, single-agent <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, or surgery alone, respectively. Main findings were as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Testicular cancer survivors had an almost twofold higher risk of metabolic syndrome compared with controls (14 versus 8 percent, respectively; odds ratio 1.9, 95% CI 1.1-3.2).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Males treated with combination chemotherapy had the highest prevalence of metabolic syndrome (17 percent). However, the prevalence among males treated with surgery alone or single-agent <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> was similar to that of healthy controls (10 and 9 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 486 testicular cancer survivors, all of whom had received first-line chemotherapy as a part of their initial treatment [<a href="#rid22">22</a>], found that the overall frequency of metabolic syndrome was similar in the testicular cancer survivors compared with a matched control group (21 versus 22 percent). However, cardiovascular risk factors were more often present among survivors, including hypertension and increased low-density lipoprotein, as well as hypogonadism and inflammation<em>,</em> but not low high-density lipoprotein and abdominal obesity.</p><p></p><p>Further discussion of the metabolic syndrome, including diagnostic criteria and an approach to treatment, is covered separately. (See  <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)</p><p class="headingAnchor" id="H773418274"><span class="h2">Gastrointestinal disorders</span><span class="headingEndMark"> — </span>Fewer males are being treated with RT for testicular cancer now compared with previously. As noted in one study, there is a slight increased risk of duodenal or gastric ulcers as a late complication in those treated with RT [<a href="#rid23">23</a>]. Biliary stenosis, a complication of radiation-induced retroperitoneal fibrosis, was also reported in another study [<a href="#rid24">24</a>]. Patients who received more than one line of treatment are at increased risk of late toxicity and death as a result of causes other than testicular cancer, including gastrointestinal toxicity [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H773414634"><span class="h2">Pulmonary toxicity</span><span class="headingEndMark"> — </span>Testicular cancer survivors are at a slight increased risk of long-term pulmonary toxicity, especially those who received chemotherapy with either <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> or <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. Pulmonary sequelae are of greatest concern in males who continue to use tobacco and smoking cessation should be encouraged. (See  <a class="medical medical_review" href="/z/d/html/17024.html" rel="external">"Treatment of alcohol use and smoking for cancer survivors"</a>.)</p><p class="headingAnchor" id="H773414661"><span class="h3">Bleomycin-induced lung injury</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">Bleomycin</a> exerts its antitumor effect by inducing programmed cell death, by inhibiting angiogenesis, and by the formation of free radicals. The enzyme required to deactivate bleomycin, bleomycin hydrolase, is not present in lung tissue and results in pulmonary injury. Short-term pulmonary complications (defined as occurring within the first three years) of bleomycin are seen in up to 46 percent of patients but most are mild and self-limited; only a small fraction of bleomycin-treated patients develop pulmonary fibrosis [<a href="#rid26">26</a>]. However, the risk of fatality in patients who develop bleomycin-associated pulmonary fibrosis is on the order of 10 percent [<a href="#rid26">26-28</a>]. In one series of 835 males with testicular cancer who had been treated with a bleomycin-containing regimen, 57 males (7 percent) developed bleomycin pulmonary toxicity, and eight males (1 percent of those receiving bleomycin and 14 percent of those with bleomycin toxicity) died as a result [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p class="headingAnchor" id="H30007340"><span class="h2">Hypogonadism</span><span class="headingEndMark"> — </span>Males treated with chemotherapy or RT are at a long-term risk for chemical hypogonadism, which is associated with infertility and poor quality of life across multiple domains, including sexual, physical, and role function [<a href="#rid29">29-32</a>]. Patients with testicular dysgenesis, a developmental condition characterized by hypospadias, cryptorchidism, poor semen quality, and testicular cancer, may also experience hypogonadism after treatment for testicular cancer. (See  <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Gonadal effects'</a> and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men", section on 'Testicular cancer'</a>.)</p><p class="headingAnchor" id="H1072939285"><span class="h3">Infertility</span><span class="headingEndMark"> — </span>Infertility is common in patients who have testicular cancer. The etiology of infertility in these males is not fully understood because testicular cancer and infertility often coexist, with many patients having evidence of impaired spermatogenesis prior to initiation of therapy. Therefore, patients with testicular cancer would benefit from evaluation of both their pre- and posttreatment reproductive status. The association between altered spermatogenesis and testicular cancer, as well as the assessment of treatment-induced infertility in males, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Gonadal effects'</a> and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men", section on 'Testicular cancer'</a> and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p>The risk of infertility is dependent on the prior treatment received [<a href="#rid33">33,34</a>]. Males treated with chemotherapy, extended-field RT, and retroperitoneal lymph node dissection (RPLND) are at greatest risk for infertility. For example, chemotherapy and RT damage spermatogenesis, whereas non-nerve-sparing RPLND impairs ejaculatory function due to surgical disruption of crucial sympathetic nerve complexes [<a href="#rid34">34</a>]. Approaches that reduce the risk of infertility include minimizing chemotherapy and RT cumulative dosing and performing nerve-sparing RPLND techniques. (See  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men", section on 'Cisplatin and testicular cancer'</a> and  <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Radiation side effects'</a> and  <a class="medical medical_review" href="/z/d/html/2992.html" rel="external">"Retroperitoneal lymph node dissection for early-stage testicular germ cell tumors", section on 'Infertility'</a>.)</p><p>In light of the significant infertility risk, sperm banking prior to the initiation of therapy is routinely discussed. (See <a class="local">'Fertility preservation'</a> above.)</p><p class="headingAnchor" id="H1072938524"><span class="h3">Sexual dysfunction</span><span class="headingEndMark"> — </span>Sexual function may be affected in testicular cancer survivors due to hypogonadism and other factors, including increasing age, lack of a partner, and heightened anxiety [<a href="#rid34">34-37</a>].</p><p>Sexual dysfunction is a poorly understood problem in testicular cancer survivors and needs further study. Data are conflicting on the frequency of sexual dysfunction in these patients. As an example, in one study, the majority (approximately three-quarters) of young males diagnosed with testicular cancer did not report sexual dysfunction or reproductive concerns two years after diagnosis [<a href="#rid38">38</a>]. In contrast, another study of approximately 1200 testicular cancer survivors reported a fourfold higher risk of erectile dysfunction; additionally, the long-term risk for erectile dysfunction was higher in patients treated with combination therapies directed at testicular cancer [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H7365631"><span class="h2">Renal impairment</span><span class="headingEndMark"> — </span>Although the greatest risk to the kidneys is during active treatment with nephrotoxic agents (eg, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>), testicular cancer survivors with such exposure are at risk for long-term chronic renal insufficiency, with the prevalence of stage 3 chronic kidney disease estimated at approximately 10 to 20 percent in one study [<a href="#rid39">39</a>]. Further details on cisplatin nephrotoxicity are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.)</p><p class="headingAnchor" id="H7365638"><span class="h2">Neurotoxicity</span><span class="headingEndMark"> — </span>Patients with testicular cancer are at increased risk for persistent peripheral neuropathy and ototoxicity, particularly if they were previously treated with a platinum-based regimen. A 2011 evaluation showed that residual platinum could be detected more than a decade following treatment and that the risk of neurotoxicity was associated with higher levels of residual platinum [<a href="#rid40">40</a>].</p><p>Impaired cognitive function and structural changes on imaging have been observed in patients treated with cisplatin-based chemotherapy [<a href="#rid41">41-44</a>]. (See  <a class="medical medical_review" href="/z/d/html/16347.html" rel="external">"Cognitive function after cancer and cancer treatment"</a>.)</p><p class="headingAnchor" id="H181279151"><span class="h2">Peripheral neuropathy</span><span class="headingEndMark"> — </span>Patients treated with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> are at risk for neuropathy that may persist long after treatment has completed. This was illustrated in a cross-sectional study of 1409 testicular cancer survivors followed for a median of 11 years [<a href="#rid45">45</a>]. Of those treated with chemotherapy, 29 percent reported paresthesias in the hands or feet. Peripheral nerve damage is a rare complication following RT [<a href="#rid46">46</a>].</p><p>Combination chemotherapy is associated with a wide range of adverse health outcomes. A study in 952 testicular cancer survivors from the Platinum Study Group found that approximately 80 percent of males had one or more treatment-related adverse events at least one year after completing therapy [<a href="#rid12">12</a>]. The most common side effects included peripheral neuropathy. (See  <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Impact of cisplatin-based chemotherapy'</a>.)</p><p class="headingAnchor" id="H7365645"><span class="h2">Ototoxicity</span><span class="headingEndMark"> — </span>Testicular cancer survivors treated with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> are at risk for developing ototoxicity in the form of hearing loss (typically at high frequencies of 3 to 8 kHz) and tinnitus at rates that are higher than the general population [<a href="#rid12">12,47,48</a>]. These toxicities can be associated with functional impairment, cognitive dysfunction, and depression [<a href="#rid49">49</a>]. Since ototoxicity is a modifiable risk factor that can be treated, we routinely screen testicular cancer survivors treated with cisplatin-based chemotherapy for hearing loss and tinnitus on history and physical exam and refer those with symptoms for formal audiology testing. (See  <a class="medical medical_review" href="/z/d/html/6850.html" rel="external">"Evaluation of hearing loss in adults"</a> and <a class="local">'Follow-up for long-term survivors of testicular cancer'</a> below.)</p><p>In observational studies, the rates of hearing loss and tinnitus (of any severity) reported in testicular cancer survivors are as high as 80 and 60 percent, respectively; between 10 to 18 percent have severe hearing loss that requires the use of a hearing aid [<a href="#rid49">49,50</a>]. Patients who receive chemotherapy are more likely to have hearing impairment and tinnitus than those who did not, and there is greater risk with increasing cycles of chemotherapy [<a href="#rid45">45</a>]. In one observational study of 243 testicular cancer survivors treated with cisplatin-based chemotherapy, those with hearing loss and tinnitus were also more likely to report significant functional impairment such as cognitive dysfunction, depression, fatigue, and worsened overall health [<a href="#rid49">49</a>]. </p><p>Further details on ototoxicity related to platinum-based chemotherapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy", section on 'Ototoxicity'</a> and  <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Impact of cisplatin-based chemotherapy'</a>.)</p><p class="headingAnchor" id="H541715451"><span class="h2">Nontraumatic osteonecrosis</span><span class="headingEndMark"> — </span>Nontraumatic osteonecrosis is most commonly seen as a complication of prolonged corticosteroid use. However, it has been reported as a rare complication of chemotherapy, particularly in males treated for testicular cancer. A 2008 literature review identified 54 cases of nontraumatic osteonecrosis, with 70 percent of these reported in testicular cancer survivors, all of whom were treated with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, and/or <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> [<a href="#rid51">51</a>]. In these reports, the femoral head was most often affected, with 75 percent experiencing bilateral involvement. However, the overall prevalence appears to be on the order of 1.5 to 4 percent [<a href="#rid52">52,53</a>].</p><p class="headingAnchor" id="H1538072322"><span class="h1">SECONDARY MALIGNANCIES</span><span class="headingEndMark"> — </span>Testicular cancer survivors have an increased risk of secondary malignancies (ie, subsequent primary cancers), including solid tumors, nonmelanoma skin cancers, and leukemias [<a href="#rid54">54,55</a>]. Contralateral testicular cancers may occur but are not common. (See  <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Risk of subsequent primary cancer'</a>.)</p><p class="headingAnchor" id="H773414863"><span class="h2">Solid tumors</span><span class="headingEndMark"> — </span>Males treated for testicular cancer have at least a twofold increased risk of developing a second solid tumor in their lifetime, especially if prior treatment consisted of both chemotherapy and radiation therapy (RT) [<a href="#rid56">56-60</a>]. This was demonstrated in one study involving 40,576 males [<a href="#rid56">56</a>]. For patients who survived at least 10 years after diagnosis, the relative risk (RR) of developing a solid tumor compared with the general population was reported as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients treated with RT, the RR was 2.0 (95% CI 1.9-2.2).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who received both RT and chemotherapy, the RR was 2.9 (95% CI 1.9-4.2).</p><p></p><p>The most common solid tumors arose from the lung, colon, bladder, pancreas, and stomach. The risk of developing a solid tumor increased over time and persisted for at least 30 years after treatment.</p><p>The risk of a second malignancy after chemotherapy as a single-modality therapy for testicular cancer appears to be elevated and remains so for years after treatment has completed. This was shown in a population-based study involving almost 13,000 males treated for testicular nonseminomatous germ cell tumors treated with either cisplatin-based chemotherapy or surgery without RT [<a href="#rid61">61</a>]. While there was no increased risk of solid tumors among males treated with surgery, treatment with chemotherapy was associated with the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A significantly increased risk of a solid cancer (standardized incidence ratio [SIR] 1.43, 95% CI 1.18-1.73), with a median latency of 12.5 years</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased risk that persisted to more than 20 years after treatment had completed</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased risk primarily for thyroid, renal, and soft tissue malignancies</p><p></p><p class="headingAnchor" id="H368653261"><span class="h2">Skin cancers</span><span class="headingEndMark"> — </span>Testicular cancer survivors are at risk for skin cancers. This was illustrated in a study on the risk of second malignancies among 29,511 testicular cancer survivors [<a href="#rid55">55</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The SIR for melanoma of the skin was 1.62 (95% CI 1.29-2.01).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonmelanoma skin cancer, the SIR was 2.26 (95% CI 1.97-2.57).</p><p></p><p>In addition, a previous study suggested that testicular cancer survivors were at an increased risk of developing dysplastic nevi compared with healthy controls (37 versus 15 percent, respectively) [<a href="#rid62">62</a>]. In that same population, two testicular cancer survivors ultimately developed melanoma.</p><p class="headingAnchor" id="H773414870"><span class="h2">Hematologic malignancies</span><span class="headingEndMark"> — </span>The risk of myelodysplastic syndrome and secondary acute leukemia is also increased after treatment for testicular cancer, particularly when the disease is diagnosed and treated at an early age [<a href="#rid63">63</a>]. In one study involving 18,567 males treated between 1970 and 1993, 36 males (0.2 percent) developed a secondary leukemia [<a href="#rid64">64</a>]. Compared with matched controls, males who developed a secondary leukemia had received a higher total dose of radiation and were more likely to have received a cisplatin-based regimen.</p><p class="headingAnchor" id="H773414877"><span class="h2">Contralateral testicular cancer</span><span class="headingEndMark"> — </span>Males with a prior history of testicular cancer are at increased risk for contralateral testicular cancer, although the overall risks are low. In several studies, this risk ranged from 1 to 3 percent over 10 to 20 years of follow-up [<a href="#rid65">65-67</a>]. Therefore, all patients should be instructed to return to their clinician as soon as possible if a contralateral testicular mass is detected. All testicular cancer survivors should have life-long follow-up care. For patients in whom a contralateral testicular cancer is detected, the psychosocial impact may be significant.</p><p class="headingAnchor" id="H181279077"><span class="h1">CHRONIC FATIGUE</span><span class="headingEndMark"> — </span>Chronic fatigue, characterized as a subjective sense of tiredness that interferes with usual functioning, has been reported in long-term testicular cancer survivors [<a href="#rid68">68,69</a>]. In one study of 1431 testicular cancer survivors followed for an average of 11 years posttreatment, chronic fatigue was noted in 17 percent compared with 10 percent among 1080 age-matched controls [<a href="#rid69">69</a>]. Chronic fatigue was associated with poor quality of life, psychosocial and somatic problems, and neuroticism. In another study, chronic fatigue was also more common in males who were less physically active and those who smoked [<a href="#rid70">70</a>]. Discussion on chronic fatigue in cancer patients and chronic fatigue syndrome, also known as myalgic encephalomyelitis/chronic fatigue syndrome, are covered separately. (See  <a class="medical medical_review" href="/z/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/2742.html" rel="external">"Treatment of myalgic encephalomyelitis/chronic fatigue syndrome"</a>.) </p><p class="headingAnchor" id="H7365681"><span class="h1">PSYCHOLOGIC DISTRESS</span><span class="headingEndMark"> — </span>Various studies highlight the importance of longitudinal follow-up for psychologic distress in long-term testicular cancer survivors [<a href="#rid71">71,72</a>].</p><p>Long-term survivors of testicular cancer have been noted to have a higher incidence of anxiety disorder than seen in the general population, but they are not at an increased risk for depression [<a href="#rid70">70,73</a>]. This was illustrated in a study of 1400 testicular cancer survivors evaluated for anxiety and depression using the Hospital Anxiety and Depression Scale [<a href="#rid73">73</a>]. Compared with age-adjusted norms, testicular cancer survivors reported a higher risk of anxiety (relative risk [RR] 1.5, 95% CI 1.3-1.7) but not depression (RR 0.96, 95% CI 0.81-1.14). Factors associated with increased anxiety included: young age, presence of peripheral neuropathy, economic problems, alcohol problems, relapse anxiety, and prior treatment for psychologic problems.</p><p>Several observational studies suggest that males with testicular cancer are at increased risk of suicide at long-term follow-up [<a href="#rid74">74,75</a>]. As an example, in one study of over 9000 males treated for stage I seminoma, at a median follow-up of 12 years, 915 (10 percent) of the males had died, and of these, 39 (4 percent) had committed suicide, making it the fifth most common cause of death in these patients [<a href="#rid74">74</a>]. Compared with an age-adjusted general male population, this represented a significantly elevated risk of death due to suicide (standardized mortality ratio 1.45, 95% CI 1.06-1.98).</p><p class="headingAnchor" id="H1048078032"><span class="h1">SURVIVORS AFTER SALVAGE THERAPY</span><span class="headingEndMark"> — </span>Patients who have relapsed after their initial therapy can often be salvaged and remain disease-free with second or subsequent lines of therapy. However, subsequent lines of therapy are associated with significantly increased toxicity in long-term survivors.</p><p>In a retrospective study of 268 patients from the Danish Testicular Cancer database who relapsed after initial radiation therapy and/or chemotherapy, 136 patients eventually died of their germ cell tumor, and 132 were salvaged with one or more chemotherapy regimens [<a href="#rid25">25</a>]. For patients requiring second or subsequent salvage therapy, the risks of death from other causes, second cancer, gastric ulcer, renal failure, and neurologic disease were significantly increased compared with patients who were disease-free after treatment with one line of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> therapy (hazard ratios [HRs] 1.7, 2.6, 3.6, 4.6, and 3.3, respectively).</p><p class="headingAnchor" id="H773415445"><span class="h1">FOLLOW-UP FOR LONG-TERM SURVIVORS OF TESTICULAR CANCER</span><span class="headingEndMark"> — </span>In view of the number of possible long-term consequences of treatment for testicular cancer and the young age at which many males undergo treatment [<a href="#rid76">76</a>], long-term follow-up is suggested.</p><p>We suggest the following surveillance for long-term testicular cancer survivors, which are generally consistent with published guidelines, including those from the National Comprehensive Cancer Network (NCCN) [<a href="#rid77">77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete physical examination annually with weight and blood pressure recorded. The examination should include a lymph node survey and examination of the contralateral testicle. An examination of the skin for dysplastic nevi should be performed. Particular attention should be paid to cardiovascular, pulmonary, and/or neurologic complaints. There should be a high index of suspicion for second cancers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Baseline lipid profile and counseling regarding cardiovascular risk factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal function (serum creatinine), serum magnesium (for patients who received cisplatin-based chemotherapy), and serum tumor markers, including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), yearly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serial assessment of hormonal function (ie, testosterone [free and total] and luteinizing hormone levels) on a regular basis, particularly for males treated with chemotherapy or radiation therapy. There are no evidence-based guidelines to inform an optimal surveillance strategy, but a reasonable approach is to test hormonal function annually in long-term survivors, especially in males who may be hypogonadal based on symptoms (eg, poor energy, sexual dysfunction, depression, fatigue) or signs (obesity, small testicular size, poor muscular development).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surveillance imaging is typically not recommended beyond five years in asymptomatic patients. However, for testicular cancer survivors who self-report new symptoms, obtaining directed imaging studies based on the symptoms (such as computed tomography [CT] imaging [<a href="#rid78">78</a>] or an ultrasound of the remaining testicle), in addition to scheduled follow-up, may detect a secondary malignancy in these patients.</p><p></p><p class="bulletIndent1">In a retrospective study of 1057 patients in long-term follow-up (consisting of yearly history, physical examination, germ cell tumor markers, abdominal CT scan, and chest radiograph), 57 males (5.4 percent) developed a secondary malignancy (after a median follow-up of 10 years) [<a href="#rid79">79</a>]. Of these, 54 percent were detected by patients (or their relatives) due to new symptoms, 29 percent by non-oncology providers (in the context of a scheduled clinical visit), and 27 percent during oncologic follow-up. Symptoms or signs of a second cancer were present in 71 percent of cases. The diagnosis was made based on new findings on imaging in 30 percent.</p><p></p><p>In addition, patients should be:</p><p class="bulletIndent1"><span class="glyph">●</span>Counseled about the importance of reporting new symptoms early.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Encouraged to adopt a healthy lifestyle, including a heart-healthy diet, regular exercise, and weight loss when needed to achieve a body mass index &lt;25 [<a href="#rid80">80,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Encouraged to avoid smoking and excess alcohol intake [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/z/d/html/17024.html" rel="external">"Treatment of alcohol use and smoking for cancer survivors"</a>.)</p><p></p><p>For those patients with persistent adverse effects from treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>Males suspected of persistent otologic toxicity should be counseled to avoid loud noise. Formal audiology testing should be performed in patients who report hearing loss or tinnitus, especially if there is a prior history of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> therapy. However, clinicians should recognize that causes unrelated to treatment may be responsible for hearing impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males with residual peripheral neuropathy should be counseled to avoid exposure to other potential neurotoxins such as alcohol. Our approach utilizes both complementary therapies (eg, physical therapy, massage, and acupuncture) and behavioral modifications aimed at helping patients recognize situations associated with increased symptoms and to avoid them. Pharmacologic options to treat neuropathic symptoms are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">"Overview of polyneuropathy", section on 'Treatment of symptoms and prevention of complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males who report difficulty with fertility issues should undergo a semen analysis and prompt referral to a reproductive endocrine specialist or urologist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males with symptoms of anxiety or distress should be referred for treatment if indicated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males with hypogonadism should be offered testosterone treatment. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p></p><p>Oncologic follow-up (with serum tumor markers, chest radiograph, and CT scan of the abdomen or abdomen and pelvis as indicated) should be coordinated between the primary oncology team and the patient's other clinical providers to ensure that services are not duplicated. For long-term cancer survivors, we offer lifelong follow-up at least annually due to the risk of late relapses and management of late effects [<a href="#rid82">82-84</a>]. The decision to extend cancer follow-up beyond 5 to 10 years with the oncology care team should be based on patient preference, risk factors for recurrence (eg, histology, risk stratification at diagnosis, treatment exposures, age, and family history, among others), availability of a cancer survivorship program, and discussion with the oncology team.</p><p>Surveillance for at least the first five years is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors", section on 'Guidelines for follow-up'</a> and  <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Coordination of care'</a>.)</p><p class="headingAnchor" id="H2659948724"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115871.html" rel="external">"Society guideline links: Neuropathic pain"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122274.html" rel="external">"Society guideline links: Testicular cancer"</a>.)</p><p class="headingAnchor" id="H181279352"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The prognosis for males with testicular cancer is excellent. Nonetheless, compared with the general population, testicular cancer survivors face a higher risk of death from non-cancer causes and long-term complications of treatment that may affect long-term quality of life. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular disease</strong> – Testicular cancer survivors are at an increased risk for cardiovascular disease, particularly among males who received chemotherapy or were treated with mediastinal radiation therapy (RT). (See <a class="local">'Cardiovascular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary toxicity</strong> – Testicular cancer survivors are at a slight increased risk of long-term pulmonary toxicity, especially in those who received <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> and continue to use tobacco. (See <a class="local">'Pulmonary toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypogonadism</strong> – Hypogonadism can be seen as a potential long-term complication from treatment of testicular cancer, particularly among males treated with extended-field RT or cisplatin-based chemotherapy. It can result in infertility and issues related to sexual dysfunction. (See <a class="local">'Hypogonadism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal impairment, neurotoxicity, and ototoxicity</strong> – Males treated with cisplatin-based chemotherapy are at increased risk for both renal dysfunction, neurotoxicity, and ototoxicity. (See <a class="local">'Renal impairment'</a> above and <a class="local">'Neurotoxicity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal function (with creatinine and magnesium levels) should be assessed annually in males who received cisplatin-based chemotherapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We routinely screen males treated with cisplatin-based chemotherapy for hearing loss and tinnitus and refer for formal audiology testing as necessary. (See <a class="local">'Ototoxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary malignancy</strong> – Males treated for testicular cancer have an increased risk of developing a second malignancy in their lifetime, especially if prior treatment consisted of both chemotherapy and RT. (See <a class="local">'Secondary malignancies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – Testicular cancer survivors should undergo a complete physical examination with serum tumor markers annually, with weight and blood pressure recorded. Particular attention should be paid to cardiovascular or neurologic complaints. (See <a class="local">'Follow-up for long-term survivors of testicular cancer'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oncologic follow-up within the first five years following diagnosis should be coordinated between the primary oncology team and the patient's other health care providers to ensure that services are not duplicated. (See <a class="local">'Follow-up posttreatment'</a> above and  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors", section on 'Guidelines for follow-up'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We offer lifelong annual follow-up for all testicular cancer survivors due to the risk of late disease relapse and second cancers. The decision to extend cancer follow-up with the oncology team beyond 5 to 10 years from diagnosis should be based on patient preference, risk factors for recurrence, availability of a cancer survivorship program, and a discussion with the primary oncology team. (See <a class="local">'Follow-up for long-term survivors of testicular cancer'</a> above.)</p><p></p><p class="headingAnchor" id="H3386971392"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Clair Beard, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gilligan T. Quality of life among testis cancer survivors. Urol Oncol 2015; 33:413.</a></li><li><a class="nounderline abstract_t">Girasole CR, Cookson MS, Smith JA Jr, et al. Sperm banking: use and outcomes in patients treated for testicular cancer. BJU Int 2007; 99:33.</a></li><li><a class="nounderline abstract_t">Woodruff TK. The Oncofertility Consortium--addressing fertility in young people with cancer. Nat Rev Clin Oncol 2010; 7:466.</a></li><li><a class="nounderline abstract_t">Jacobs LA, Vaughn DJ. Hypogonadism and infertility in testicular cancer survivors. J Natl Compr Canc Netw 2012; 10:558.</a></li><li><a class="nounderline abstract_t">Weibring K, Nord C, Ståhl O, et al. Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment. Ann Oncol 2019; 30:604.</a></li><li><a class="nounderline abstract_t">Bayens YC, Helle PA, Van Putten WL, Mali SP. Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. Radiother Oncol 1992; 25:97.</a></li><li><a class="nounderline abstract_t">Ellerbroek NA, Tran LM, Selch MT, et al. Testicular seminoma. A study of 103 cases treated at UCLA. Am J Clin Oncol 1988; 11:93.</a></li><li class="breakAll">Daugaard G, Roerth M. Observation and expectant management for low-stage seminoma and nonseminoma. In: Comprehensive Textbook of Genitourinary Oncology, 2nd ed, Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (Eds), Lippincott, Williams and Wilkins, Philadelphia 2000. p.976.</li><li><a class="nounderline abstract_t">Oldenburg J, Alfsen GC, Waehre H, Fosså SD. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer 2006; 94:820.</a></li><li><a class="nounderline abstract_t">Geldart TR, Gale J, McKendrick J, et al. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int 2006; 98:353.</a></li><li><a class="nounderline abstract_t">Nayan M, Hamilton RJ. Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer. Adv Urol 2018; 2018:7182014.</a></li><li><a class="nounderline abstract_t">Fung C, Sesso HD, Williams AM, et al. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. J Clin Oncol 2017; 35:1211.</a></li><li><a class="nounderline abstract_t">Gerl A, Schierl R. Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol 2000; 39:519.</a></li><li><a class="nounderline abstract_t">Groot HJ, van Leeuwen FE, Lubberts S, et al. Platinum exposure and cause-specific mortality among patients with testicular cancer. Cancer 2020; 126:628.</a></li><li><a class="nounderline abstract_t">Kerns SL, Fung C, Monahan PO, et al. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. J Clin Oncol 2018; 36:1505.</a></li><li><a class="nounderline abstract_t">Lauritsen J, Hansen MK, Bandak M, et al. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. J Clin Oncol 2020; 38:584.</a></li><li><a class="nounderline abstract_t">Fung C, Dinh PC, Fossa SD, Travis LB. Testicular Cancer Survivorship. J Natl Compr Canc Netw 2019; 17:1557.</a></li><li><a class="nounderline abstract_t">Clasen SC, Fung C, Dinh PC Jr, Travis LB. Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer. J Clin Oncol 2020; 38:1497.</a></li><li><a class="nounderline abstract_t">Fung C, Fossa SD, Milano MT, et al. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. J Clin Oncol 2015; 33:3105.</a></li><li><a class="nounderline abstract_t">Lubberts S, Groot HJ, de Wit R, et al. Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life. J Clin Oncol 2023; 41:3512.</a></li><li><a class="nounderline abstract_t">Willemse PM, Burggraaf J, Hamdy NA, et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer 2013; 109:60.</a></li><li><a class="nounderline abstract_t">Zaid MA, Gathirua-Mwangi WG, Fung C, et al. Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. J Natl Compr Canc Netw 2018; 16:257.</a></li><li><a class="nounderline abstract_t">Hamilton CR, Horwich A, Bliss JM, Peckham MJ. Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. Radiother Oncol 1987; 10:85.</a></li><li><a class="nounderline abstract_t">Stensvold E, Aass N, Gladhaug I, et al. Erroneous diagnosis of pancreatic cancer after radiotherapy of testicular cancer. Eur J Surg Oncol 2004; 30:352.</a></li><li><a class="nounderline abstract_t">Lauritsen J, Kier MG, Mortensen MS, et al. Germ Cell Cancer and Multiple Relapses: Toxicity and Survival. J Clin Oncol 2015; 33:3116.</a></li><li><a class="nounderline abstract_t">Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120:617.</a></li><li><a class="nounderline abstract_t">Dearnaley DP, Horwich A, A'Hern R, et al. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer 1991; 27:684.</a></li><li><a class="nounderline abstract_t">O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14:91.</a></li><li><a class="nounderline abstract_t">Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005; 93:200.</a></li><li><a class="nounderline abstract_t">Huddart RA, Birtle AJ. Recent advances in the treatment of testicular cancer. Expert Rev Anticancer Ther 2005; 5:123.</a></li><li><a class="nounderline abstract_t">Nord C, Bjøro T, Ellingsen D, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003; 44:322.</a></li><li><a class="nounderline abstract_t">Oldenburg J. Hypogonadism and fertility issues following primary treatment for testicular cancer. Urol Oncol 2015; 33:407.</a></li><li><a class="nounderline abstract_t">Brydøy M, Fosså SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97:1580.</a></li><li><a class="nounderline abstract_t">Hamano I, Hatakeyama S, Ohyama C. Fertility preservation of patients with testicular cancer. Reprod Med Biol 2017; 16:240.</a></li><li><a class="nounderline abstract_t">Vehling S, Mehnert A, Hartmann M, et al. Anxiety and depression in long-term testicular germ cell tumor survivors. Gen Hosp Psychiatry 2016; 38:21.</a></li><li><a class="nounderline abstract_t">Abu Zaid M, Dinh PC, Monahan PO, et al. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. J Natl Compr Canc Netw 2019; 17:459.</a></li><li><a class="nounderline abstract_t">Dahl AA, Bremnes R, Dahl O, et al. Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 2007; 52:1438.</a></li><li><a class="nounderline abstract_t">Ljungman L, Eriksson LE, Flynn KE, et al. Sexual Dysfunction and Reproductive Concerns in Young Men Diagnosed With Testicular Cancer: An Observational Study. J Sex Med 2019; 16:1049.</a></li><li><a class="nounderline abstract_t">Kawai K, Ichioka D, Inai H, et al. Assessment and management of renal impairment in chemotherapy for urogenital cancer. Jpn J Clin Oncol 2013; 43:1055.</a></li><li><a class="nounderline abstract_t">Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012; 30:300.</a></li><li><a class="nounderline abstract_t">Amidi A, Hosseini SMH, Leemans A, et al. Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy. J Natl Cancer Inst 2017; 109.</a></li><li><a class="nounderline abstract_t">Amidi A, Agerbæk M, Wu LM, et al. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav 2017; 11:769.</a></li><li><a class="nounderline abstract_t">Wefel JS, Vidrine DJ, Marani SK, et al. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology 2014; 23:626.</a></li><li><a class="nounderline abstract_t">Stouten-Kemperman MM, de Ruiter MB, Caan MW, et al. Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy. Hum Brain Mapp 2015; 36:4638.</a></li><li><a class="nounderline abstract_t">Brydøy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009; 101:1682.</a></li><li><a class="nounderline abstract_t">Gikas PD, Hanna SA, Aston W, et al. Post-radiation sciatic neuropathy: a case report and review of the literature. World J Surg Oncol 2008; 6:130.</a></li><li><a class="nounderline abstract_t">Bauer CA, Brozoski TJ. Cochlear structure and function after round window application of ototoxins. Hear Res 2005; 201:121.</a></li><li><a class="nounderline abstract_t">Stava C, Beck M, Schultz PN, Vassilopoulou-Sellin R. Hearing loss among cancer survivors. Oncol Rep 2005; 13:1193.</a></li><li><a class="nounderline abstract_t">Sanchez VA, Shuey MM, Dinh PC Jr, et al. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy. J Clin Oncol 2023; 41:2211.</a></li><li><a class="nounderline abstract_t">Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol 2016; 34:2712.</a></li><li><a class="nounderline abstract_t">Shim K, MacKenzie MJ, Winquist E. Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review. Drug Saf 2008; 31:359.</a></li><li><a class="nounderline abstract_t">Cook AM, Dzik-Jurasz AS, Padhani AR, et al. The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. Br J Cancer 2001; 85:1624.</a></li><li><a class="nounderline abstract_t">Winquist EW, Bauman GS, Balogh J. Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am J Clin Oncol 2001; 24:603.</a></li><li><a class="nounderline abstract_t">Fung C, Fossa SD, Beard CJ, Travis LB. Second malignant neoplasms in testicular cancer survivors. J Natl Compr Canc Netw 2012; 10:545.</a></li><li><a class="nounderline abstract_t">Richiardi L, Scélo G, Boffetta P, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 2007; 120:623.</a></li><li><a class="nounderline abstract_t">Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97:1354.</a></li><li><a class="nounderline abstract_t">Wanderås EH, Fosså SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 1997; 33:253.</a></li><li><a class="nounderline abstract_t">van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25:4370.</a></li><li><a class="nounderline abstract_t">Richie JP. Re: Second Cancers and Causes of Death in Patients with Testicular Cancer in Sweden. J Urol 2019; 202:867.</a></li><li><a class="nounderline abstract_t">Hellesnes R, Myklebust TÅ, Fosså SD, et al. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort. J Clin Oncol 2021; 39:3561.</a></li><li><a class="nounderline abstract_t">Fung C, Fossa SD, Milano MT, et al. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 2013; 31:3807.</a></li><li><a class="nounderline abstract_t">Raghavan D, Zalcberg JR, Grygiel JJ, et al. Multiple atypical nevi: a cutaneous marker of germ cell tumors. J Clin Oncol 1994; 12:2284.</a></li><li><a class="nounderline abstract_t">Morton LM, Dores GM, Schonfeld SJ, et al. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. JAMA Oncol 2019; 5:318.</a></li><li><a class="nounderline abstract_t">Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000; 92:1165.</a></li><li><a class="nounderline abstract_t">Fosså SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005; 97:1056.</a></li><li><a class="nounderline abstract_t">Zequi Sde C, da Costa WH, Santana TB, et al. Bilateral testicular germ cell tumours: a systematic review. BJU Int 2012; 110:1102.</a></li><li><a class="nounderline abstract_t">Kopp RP, Chevinsky M, Bernstein M, et al. Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. Urology 2017; 103:154.</a></li><li><a class="nounderline abstract_t">Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park) 2000; 14:151.</a></li><li><a class="nounderline abstract_t">Orre IJ, Fosså SD, Murison R, et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 2008; 64:363.</a></li><li><a class="nounderline abstract_t">Thorsen L, Nystad W, Stigum H, et al. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer 2005; 13:637.</a></li><li><a class="nounderline abstract_t">Raphael MJ, Gupta S, Wei X, et al. Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. J Clin Oncol 2021; 39:779.</a></li><li><a class="nounderline abstract_t">Fosså SD, Dahl AA, Thorsen L, et al. Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors. J Clin Oncol 2022; 40:2588.</a></li><li><a class="nounderline abstract_t">Dahl AA, Haaland CF, Mykletun A, et al. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol 2005; 23:2389.</a></li><li><a class="nounderline abstract_t">Beard CJ, Travis LB, Chen MH, et al. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer 2013; 119:2771.</a></li><li><a class="nounderline abstract_t">Gunnes MW, Lie RT, Bjørge T, et al. Suicide and violent deaths in survivors of cancer in childhood, adolescence and young adulthood-A national cohort study. Int J Cancer 2017; 140:575.</a></li><li><a class="nounderline abstract_t">Shaikh F, Stark D, Fonseca A, et al. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium. Cancer 2021; 127:193.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) guidelines: Testicular Cancer. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf (Accessed on February 01, 2022).</li><li><a class="nounderline abstract_t">Huned D, Tiwari RV, Lee LS. Unusual finding after treatment for testicular cancer. BMJ Case Rep 2021; 14.</a></li><li><a class="nounderline abstract_t">Buchler T, Kubankova P, Boublikova L, et al. Detection of second malignancies during long-term follow-up of testicular cancer survivors. Cancer 2011; 117:4212.</a></li><li><a class="nounderline abstract_t">Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw 2012; 10:537.</a></li><li><a class="nounderline abstract_t">Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62:243.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Agarwal N, Beard C, et al. Testicular cancer. J Natl Compr Canc Netw 2012; 10:502.</a></li><li><a class="nounderline abstract_t">Tralongo P, Surbone A, Serraino D, Dal Maso L. Major patterns of cancer cure: Clinical implications. Eur J Cancer Care (Engl) 2019; 28:e13139.</a></li><li><a class="nounderline abstract_t">Maroto P, Anguera G, Martin C. Long-term toxicity of the treatment for germ cell-cancer. A review. Crit Rev Oncol Hematol 2018; 121:62.</a></li></ol></div><div id="topicVersionRevision">Topic 14236 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26087970" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Quality of life among testis cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17034492" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sperm banking: use and outcomes in patients treated for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498666" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Oncofertility Consortium--addressing fertility in young people with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491052" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypogonadism and infertility in testicular cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30798330" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1438941" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3358365" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Testicular seminoma. A study of 103 cases treated at UCLA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3358365" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Testicular seminoma. A study of 103 cases treated at UCLA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508636" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Late recurrences of germ cell malignancies: a population-based experience over three decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16879677" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29670653" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28240972" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041115" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31730712" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Platinum exposure and cause-specific mortality among patients with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29617189" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31821065" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31805527" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Testicular Cancer Survivorship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32186943" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26240226" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37071834" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23660945" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29523664" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3423305" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028321" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Erroneous diagnosis of pancreatic cancer after radiotherapy of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26240225" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Germ Cell Cancer and Multiple Relapses: Toxicity and Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502668" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bleomycin-induced pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1712606" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488299" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15999104" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fertility, gonadal and sexual function in survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15757445" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Recent advances in the treatment of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12932930" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25736189" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypogonadism and fertility issues following primary treatment for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16264178" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Paternity following treatment for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29259474" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fertility preservation of patients with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26439320" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Anxiety and depression in long-term testicular germ cell tumor survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31085753" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17350159" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Is the sexual function compromised in long-term testicular cancer survivors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31255211" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sexual Dysfunction and Reproductive Concerns in Young Men Diagnosed With Testicular Cancer: An Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24031085" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Assessment and management of renal impairment in chemotherapy for urogenital cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184390" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29617869" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27240852" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24339329" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A prospective study of cognitive function in men with non-seminomatous germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304182" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940282" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077234" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Post-radiation sciatic neuropathy: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15721567" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cochlear structure and function after round window application of ototoxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870942" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hearing loss among cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36626694" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27354478" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422377" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11742478" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11801763" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491051" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Second malignant neoplasms in testicular cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17096341" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174857" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135497" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17906202" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31380710" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Re: Second Cancers and Causes of Death in Patients with Testicular Cancer in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34388002" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24043737" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7964941" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Multiple atypical nevi: a cutaneous marker of germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30570657" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10904090" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment-associated leukemia following testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16030303" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22429248" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Bilateral testicular germ cell tumours: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816603" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11195408" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : NCCN Practice Guidelines for Cancer-Related Fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374735" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chronic cancer-related fatigue in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15756585" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33507821" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35380874" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800331" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Study of anxiety disorder and depression in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633409" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Outcomes in stage I testicular seminoma: a population-based study of 9193 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27750385" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Suicide and violent deaths in survivors of cancer in childhood, adolescence and young adulthood-A national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33079404" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33079404" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33419745" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Unusual finding after treatment for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21480199" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Detection of second malignancies during long-term follow-up of testicular cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491050" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Late cardiovascular toxicity following chemotherapy for germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22539238" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nutrition and physical activity guidelines for cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491049" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31436897" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Major patterns of cancer cure: Clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29279100" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Long-term toxicity of the treatment for germ cell-cancer. A review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
